U.S. markets closed
  • S&P 500

    4,228.48
    -55.26 (-1.29%)
     
  • Dow 30

    33,706.74
    -292.30 (-0.86%)
     
  • Nasdaq

    12,705.21
    -260.13 (-2.01%)
     
  • Russell 2000

    1,957.35
    -43.38 (-2.17%)
     
  • Crude Oil

    89.91
    -0.59 (-0.65%)
     
  • Gold

    1,760.30
    -10.90 (-0.62%)
     
  • Silver

    18.97
    -0.50 (-2.56%)
     
  • EUR/USD

    1.0044
    -0.0048 (-0.47%)
     
  • 10-Yr Bond

    2.9890
    +0.1090 (+3.78%)
     
  • GBP/USD

    1.1823
    -0.0109 (-0.92%)
     
  • USD/JPY

    136.9300
    +1.0680 (+0.79%)
     
  • BTC-USD

    21,137.46
    -1,639.88 (-7.20%)
     
  • CMC Crypto 200

    504.88
    -36.72 (-6.78%)
     
  • FTSE 100

    7,550.37
    +8.52 (+0.11%)
     
  • Nikkei 225

    28,930.33
    -11.81 (-0.04%)
     

Ultragenyx's (RARE) Q4 Earnings & Revenues Miss Estimates

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Ultragenyx Pharmaceutical Inc. RARE incurred a loss of $1.79 per share for fourth-quarter 2021, wider than the Zacks Consensus Estimate of a loss of $1.32. The company reported a loss of $1.34 per share in the year-ago quarter.

Ultragenyx’s total revenues of $83.4 million in the fourth quarter declined 8.8% year over year. The top line slightly missed the Zacks Consensus Estimate of $84 million.

Shares of Ultragenyx have plunged 56.2% in the past year compared with the industry's decline of 38.3%.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

Ultragenyx markets three drugs, namely Crysvita, Mepsevii and Dojolvi. Crysvita is approved for the treatment of X-linked hypophosphatemia, an inherited disorder; and tumor-induced osteomalacia, an ultra-rare disease. Mepsevii is approved to treat Mucopolysaccharidosis VII (MPS VII), also known as Sly syndrome. Dojolvi was approved in June 2020 for all forms of long-chain fatty acid oxidation disorders (LC-FAOD).

Full-Year Results

For 2021, Ultragenyx generated total revenues of $351.4 million compared with $271 million recorded in 2020.

For full-year 2021, the company reported a loss of $6.70 per share compared with net loss of $3.07 per share in 2020.

Quarter in Detail

Crysvita’s total revenues were $60.2 million, up 36.8% year over year, driven by increased demand for both approved indications. Crysvita revenues in Ultragenyx territories rose 37.2% to $55.4 million in the quarter and included $50.2 million from the North America profit share territory as well as $5.3 million of net product sales for the drug in other regions. Total royalty revenues related to the sales of Crysvita in the European territory were $4.7 million. Ultragenyx sold its Crysvita rights in the European territory to Royalty Pharma in December 2019.

Mepsevii product revenues were $3.1 million in the quarter compared with $3.6 million reported in the year-ago quarter. Dojolvi product revenues were $11.8 million compared with $6.4 million in the year-ago quarter, driven by strong new patient demand. Revenues in the quarter also included $8.2 million in relation to Ultragenyx’s collaboration and license agreement with Daiichi Sankyo.

Operating expenses decreased 0.9% to $185.9 million in the quarter due to pipeline advancements. The company continues to support its six clinical programs that are currently enrolling patients.

In January 2022, Ultragenyx announced a license and collaboration agreement with Regeneron Pharmaceuticals REGN. Per the deal, Ultragenyx has obtained rights to develop, commercialize and distribute Evkeeza (evinacumab) outside the United States. The regions include the European Economic Area.

Evkeeza is approved in these regions for use with diet and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies to treat patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH).

Evkeeza was discovered and developed by Regeneron. REGN launched the medicine in the United States in February 2021.

Please note that the collaboration with Regeneron for Evkeeza gives Ultragenyx a fourth approved product that can add to its revenues along with Crysvita, Mepsevii, and Dojolvi.

2022 Guidance

The company expects Crysvita revenues to be in the range of $250-$260 million in Ultragenyx territories. Dojolvi revenues are expected in the band of $55-$65 million.

Pipeline Updates

In October 2021, Ultragenyx initiated a seamless phase I/II/III study on UX701, an AAV type 9 gene therapy product candidate, for the treatment of Wilson disease — a rare metabolic disease.

Ultragenyx, along with partner GeneTx, is developing GTX-102 for treating patients with Angelman syndrome. In October 2021, the company dosed the first patient in a phase I/II study on GTX-102 for treating patients with Angelman syndrome in Canada. In September 2021, the FDA removed the clinical hold from the phase I/II study evaluating GTX-102 for the treatment of Angelman syndrome.

Ultragenyx Pharmaceutical Inc. Price, Consensus and EPS Surprise

Ultragenyx Pharmaceutical Inc. Price, Consensus and EPS Surprise
Ultragenyx Pharmaceutical Inc. Price, Consensus and EPS Surprise

Ultragenyx Pharmaceutical Inc. price-consensus-eps-surprise-chart | Ultragenyx Pharmaceutical Inc. Quote

Zacks Rank & Stock to Consider

Ultragenyx currently carries a Zacks Rank #4 (Sell).

Better-ranked stocks in the biotech sector include Axsome Therapeutics, Inc. AXSM and Editas Medicine, Inc. EDIT, both sportinga Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Axsome Therapeutics’ loss per share estimates have narrowed 0.8% for 2022 over the past 60 days.

Earnings of Axsome Therapeutics have surpassed estimates in three of the trailing four quarters, and missed the same on the other occasion.

Editas Medicine’s loss per share estimates have narrowed 1.4% for 2022 over the past 60 days.

Earnings of Editas Medicine have surpassed estimates in two of the trailing four quarters, and missed the same on the other two occasions.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report

Ultragenyx Pharmaceutical Inc. (RARE) : Free Stock Analysis Report

Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report

Editas Medicine, Inc. (EDIT) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research